专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017134061A1 TRUNCATED GLYCOPROTEIN G OF HERPES SIMPLEX VIRUS 2 审中-公开
标题翻译：截短的疱疹单纯疱疹病毒G蛋白2
公开(公告)号：WO2017134061A1
公开(公告)日：2017-08-10
申请号：PCT/EP2017/052070
申请日：2017-01-31
申请人： GU VENTURES AB
发明人： LILJEQVIST, Jan-Åke
IPC分类号： C07K14/005 , A61K39/245 , G01N33/569 , A61K39/00
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/70 , C12N2710/16022 , C12N2710/16034 , C12N2710/16071 , G01N33/56994
摘要： The present invention relates to a protein comprising a truncated version of the HSV- 2 protein mg G-2, said protein comprising: (i) an extracellular region of mg G-2 (EX-mg G-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90 %, 95 %, 96 %, 97 %, 98 % or 99 % sequence identity (%SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3; (ii) a truncated transmembrane region of mg G-2 (t-TMR-mg G-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90 % sequence identity (%SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and (iii) an intracellular region of mg G-2 (IC-mg G-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90 % or 95 % sequence identity (%SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.
摘要翻译：本发明涉及包含截短形式的HSV-2蛋白mg G-2的蛋白质，所述蛋白质包含：（i）mg G-2的胞外区（EX-mg G -2）或其截短形式，至少285个氨基酸; 所述胞外区或其截短形式与SEQ ID NO：3中存在的相应长度的肽片段具有至少90％，95％，96％，97％，98％或99％的序列同一性（％SI）（ii）2至15个氨基酸的mg G-2（t-TMR-mg G-2）的截短跨膜区; 所述截短的跨膜区域与存在于SEQ ID NO：6中的相应长度的肽片段具有至少90％的序列同一性（％SI）和（iii）至少18个氨基酸的mg G-2胞内区（IC-mg G-2）或其截短形式; 所述细胞内区域或其截短形式与存在于SEQ ID NO：8中的相应长度的肽片段具有至少90％或95％的序列同一性（％SI）。

2. 发明申请

WO2016141320A2 NON-NEUROINVASIVE VIRUSES AND USES THEREOF 审中-公开
标题翻译：非神经免疫病毒及其用途
公开(公告)号：WO2016141320A2
公开(公告)日：2016-09-09
申请号：PCT/US2016/020960
申请日：2016-03-04
申请人： NORTHWESTERN UNIVERSITY , BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA , TRUSTEES OF TUFTS COLLEGE (AKA TUFTS UNIVERSITY)
发明人： SMITH, Gregory A. , SOLLARS, Patricia Jane , PICKARD, Gary Edward , HELDWEIN, Ekaterina E.
IPC分类号： A61K39/12 , C12N7/00
CPC分类号： C12N7/00 , A61K35/763 , A61K39/12 , A61K39/245 , A61K39/25 , A61K2039/5254 , C07K14/005 , C07K2299/00 , C12N2710/16034 , C12N2710/16621 , C12N2710/16622 , C12N2710/16632 , C12N2710/16633 , C12N2710/16634 , C12N2710/16643 , C12N2710/16721 , C12N2710/16722 , C12N2710/16732 , C12N2710/16733 , C12N2710/16734 , C12N2710/16743
摘要： Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.
摘要翻译：本文提供用于疫苗接种和研究应用的组合物和方法。具体而言，本文提供了非神经侵袭性疱疹病毒和α疱疹病毒及其用途。

3. 发明申请

WO2016030392A1 NOVEL IMMUNIZATION AGENTS AND METHODS OF USE 审中-公开
标题翻译：新型免疫剂及其使用方法
公开(公告)号：WO2016030392A1
公开(公告)日：2016-03-03
申请号：PCT/EP2015/069472
申请日：2015-08-25
申请人： HSF PHARMACEUTICALS
发明人： VOELLMY, Richard , BLOOM, David C.
IPC分类号： A61K39/12 , A61K39/00
CPC分类号： A61K39/12 , A61K2039/5254 , C12N2710/10334 , C12N2710/10343 , C12N2710/16034 , C12N2710/16611 , C12N2710/16634 , C12N2710/16643 , C12N2800/40 , C12N2830/002
摘要： The present invention relates to a vaccine composition comprising an effective amount of a replication-competent controlled recombinant virus. Further encompassed are uses in immunization and methods of immunization employing compositions comprising a replication-competent controlled recombinant virus of the invention.
摘要翻译：本发明涉及包含有效量的可复制受控重组病毒的疫苗组合物。进一步包括免疫中的用途和免疫方法，其使用包含本发明的具有复制能力的受控重组病毒的组合物。

4. 发明申请

WO2016020885A1 VACUNA EN VECTOR RECOMBINANTE DE ADENOVIRUS AVIAR SEROTIPO 9 审中-公开
标题翻译：重组血清型9型AVIAN腺病毒载体中的疫苗
公开(公告)号：WO2016020885A1
公开(公告)日：2016-02-11
申请号：PCT/IB2015/055994
申请日：2015-08-06
申请人： LABORATORIO AVI-MEX, S.A. DE C.V.
发明人： LOZANO-DUBERNARD, Bernardo , SOTO-PRIANTE, Ernesto , SARFATI-MIZRAHI, David
IPC分类号： C12N15/861 , A61K39/12 , A61K39/145 , A61K39/245 , A61K39/215 , A61K39/112
CPC分类号： A61K39/145 , A61K39/12 , A61K39/245 , A61K2039/5252 , A61K2039/5256 , A61K2039/545 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/10221 , C12N2710/10234 , C12N2710/10243 , C12N2710/10271 , C12N2710/16034 , C12N2710/16071 , C12N2760/16134 , C12N2760/16171
摘要： Se describe una vacuna recombinante que comprende un vector de adenovirus aviar serotipo 9 (FAdV-9) que tiene insertada por lo menos una secuencia de nucleótidos exógena que codifica para por lo menos un antígeno de una enfermedad de interés y que reemplaza la región no esencial del genoma del adenovirus, y un vehículo, adyuvante y/o excipiente farmacéuticamente aceptable, en donde la por lo menos una secuencia de nucleótidos exógena que codifica para por lo menos un antígeno de una enfermedad de interés y que reemplaza la región no esencial del genoma del adenovirus se localiza entre los nucleótidos 491-2782. El vector de esta vacuna es estable para producción a escala industrial. Asimismo, aún cuando esta vacuna se administra en combinación con una vacuna contra la enfermedad de Marek, ambas producen una respuesta inmune adecuada que no se ve afectada por la interferencia entre ellas. De la misma manera, la efectividad de la vacuna recombinante no se ve afectada por los anticuerpos maternos, y es capaz de inducir una respuesta protectora tanto temprana como duradera, aún con una sola aplicación.
摘要翻译：给出了包含血清型9型禽类腺病毒载体（FAdV-9）的重组疫苗的描述，其中插入了至少一种编码感兴趣的疾病的至少一种抗原的外源核苷酸序列，腺病毒基因组的必需区域，以及药学上可接受的载体，佐剂和/或赋形剂，其中所述至少一种外源核苷酸序列编码感兴趣的疾病的至少一种抗原并且替代所述非必需区域腺病毒基因组位于核苷酸491-2782之间。该疫苗的载体对于工业规模的生产是稳定的。同样，即使这种疫苗与针对马立克氏病的疫苗组合施用，两种疫苗产生足够的免疫应答，其不受它们之间的干扰影响。类似地，重组疫苗的功效不受母体抗体的影响，并且能够诱导早期和持久的保护性反应，甚至在单一应用中。

5. 发明申请

WO2013090296A1 COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND METHODS OF USING THE SAME 审中-公开
标题翻译：包含改进的IL-12遗传构建体和疫苗的组合物，免疫球蛋白及其使用方法
公开(公告)号：WO2013090296A1
公开(公告)日：2013-06-20
申请号：PCT/US2012/069017
申请日：2012-12-11
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
发明人： WEINER, David, B , MORROW, Matthew, P , YAN, Jian
IPC分类号： C07H15/24
CPC分类号： A61K39/39 , A61K38/20 , A61K38/208 , A61K38/2086 , A61K39/0005 , A61K39/0011 , A61K39/245 , A61K39/292 , A61K41/00 , A61K2039/525 , A61K2039/53 , A61K2039/55538 , C07K14/5434 , C12N7/00 , C12N2510/00 , C12N2710/16034 , C12N2730/10134 , C12N2730/10171
摘要： Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL-12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. Method of modulating immune response and methods of inducing an immune response against an immunogen are disclosed. Therapeutic and prophylactic vaccination methods are also disclosed.
摘要翻译：公开了包含编码IL-12p35亚基或其功能片段和/或编码IL-12p40亚基或其功能片段的核酸序列的核酸序列的核酸分子和组合物。还公开了进一步包含编码免疫原的核酸序列的核酸分子和组合物。公开了调节免疫应答的方法和诱导针对免疫原的免疫应答的方法。还公开了治疗和预防性接种方法。

6. 发明申请

WO2012018813A2 MODIFIED INFECTIOUS LARYNGOTRACHEITIS VIRUS (ILTV) AND USES THEREOF 审中-公开
标题翻译：改良感染性喉镜病毒（ILTV）及其用途
公开(公告)号：WO2012018813A2
公开(公告)日：2012-02-09
申请号：PCT/US2011/046263
申请日：2011-08-02
申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. , GARCIA, Maricarmen , MUNDT, Alice , MUNDT, Egbert
发明人： GARCIA, Maricarmen , MUNDT, Alice , MUNDT, Egbert
IPC分类号： A61K39/245 , C12N15/34 , A61P31/20
CPC分类号： A61K39/12 , A61K35/76 , A61K39/265 , A61K2039/5254 , A61K2039/54 , A61K2039/552 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/16021 , C12N2710/16022 , C12N2710/16034 , C12N2710/16043 , C12N2710/16062 , C12N2760/18134
摘要： Provided herein are modified infectious laryngotracheitis viruses (ILTVs) and methods of using the same. For example, provided are attenuated ILTVs. The attenuated ILTVs can be used to illicit immune responses in avian species. Optionally, the attenuated ILTVs can be used to vaccinate an avian subject or a population of avian subjects. Optionally, an attenuated ILTV is administered in ovo to an avian egg. One or more such in ovo administration can be used to increase the immunity of an avian herd.
摘要翻译：本文提供修饰的感染性喉气管炎病毒（ILTV）及其使用方法。例如，提供的是衰减的ILTV。减毒的ILTV可用于非法禽类物种的免疫应答。任选地，减毒的ILTV可用于接种禽类受试者或禽类受试者群体。任选地，减毒的ILTV以卵子方式施用于禽类卵。可以使用一个或多个在卵内管理中来增加禽群的免疫力。

7. 发明申请

WO02074335A3 EQUINE HERPESVIRUS VACCINE 审中-公开
公开(公告)号：WO02074335A3
公开(公告)日：2003-07-17
申请号：PCT/US0201644
申请日：2002-01-23
申请人： BOEHRINGER INGELHEIM VETMED
发明人： MELLENCAMP MARK W
IPC分类号： A61K39/145 , A61K39/245 , A61K39/27 , A61K39/295 , A61K39/39 , A61K45/08 , A61P31/12 , C07K16/08 , C12N7/06 , C12N7/04
CPC分类号： C07K16/087 , A61K39/12 , A61K39/145 , A61K39/245 , A61K39/27 , A61K39/39 , A61K2039/5252 , A61K2039/54 , A61K2039/543 , A61K2039/545 , A61K2039/552 , A61K2039/55511 , A61K2039/55555 , A61K2039/70 , C07K2317/76 , C12N2710/16034 , C12N2710/16734 , C12N2710/16763 , C12N2760/16134 , C12N2760/16163
摘要： A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus), using ethylenimine and an adjuvant. The adjuvant can include a cross-linked olefinically unsaturated carboxylic acid polymer which may have bioadhesive properties. The vaccine may also include antigens against other equine pathogens such as inactivated EHV-4 and inactivated A1 and/or A2 strains of equine influenza virus. Methods for protecting horses against diseases associated with EHV-1 and/or EHV-4 and methods of producing the equine herpesvirus vaccine are also provided.
摘要翻译：提供了一种用于保护马免受与EHV-1和/或EHV-4有关的疾病的疫苗。疫苗通常包括使用乙烯亚胺和佐剂的灭活的EHV-1（例如化学灭活的EHV-1 KyA病毒）。佐剂可以包括可具有生物粘附性质的交联的烯属不饱和羧酸聚合物。疫苗还可以包括针对其他马病原体的抗原，例如灭活的EHV-4和灭活的A1和/或A2株马流感病毒。还提供了用于保护马免受与EHV-1和/或EHV-4相关的疾病的方法和产生马疱疹病毒疫苗的方法。

8. 发明申请

WO2003054212A2 A METHOD AND COMPOSITIONS FOR CONFERRING VIRAL IMMUNITY AND REVERSING VIRAL PATHOGENESIS VIA STRATEGIC INFECTION WITH A THERAVIRUS THEREBY PROVIDING GENOMIC INTEGRATION OF GENETICALLY ENGINEERED, REPLICATION INCOMPETENT, INTEGRATING VIRAL DNA 审中-公开
标题翻译：用于通过具有遗传性传播的遗传性感染的遗传性感染来传播病毒性免疫和逆转病毒感染的方法和组合物，其提供遗传工程，复制不一致性，整合病毒DNA的基因组整合
公开(公告)号：WO2003054212A2
公开(公告)日：2003-07-03
申请号：PCT/US2002/037081
申请日：2002-11-19
申请人： GLACER, Lawrence, F.
发明人： GLACER, Lawrence, F.
IPC分类号： C12Q
CPC分类号： A61K39/12 , A61K2039/5254 , C12N2710/16034 , C12N2740/16034
摘要： The present invention provides a method of conferring viral immunity and/or reversing viral pathogenesis via strategic genomic integration of a genetically engineered replication incompetent vDNA composition, ie., a theravirus. The invention is generally effectuated by administering to a host a therapeutic amount of genetically engineered viral DNA (vDNA) composition in an amount sufficient to out-compete the natural pathogenic vDNA's ability to integrate into the host cells genome. The genetically engineered vDNA construct is genetically altered in a manner that effectively prevents post integration transcription of the composition. The invention is effective in the prevention and treatment of viral infections, including, HIV (AIDS), herpes and hepatitis.
摘要翻译：本发明提供了一种赋予病毒免疫和/或逆转病毒发病机制的方法，该方法是通过基因工程复制不足vDNA组合（即热病毒）的战略基因组整合。本发明通常通过向宿主施用足以抵抗天然病原性vDNA整合入宿主细胞基因组的能力的治疗量的基因工程化病毒DNA（vDNA）组合物来实现。遗传改造的vDNA构建体以有效地防止组合物的后整合转录的方式进行遗传改变。本发明有效预防和治疗病毒感染，包括HIV（艾滋病），疱疹和肝炎。

9. 发明申请

WO00023103A1 VIRAL MASTITIS 审中-公开
公开(公告)号：WO00023103A1
公开(公告)日：2000-04-27
申请号：PCT/NL1999/000645
申请日：1999-10-18
IPC分类号： A61K39/245 , A61P31/12 , C12N7/00 , A01N63/00 , A61P31/20
CPC分类号： C12N7/00 , A61K39/12 , A61K39/245 , A61K2039/525 , C12N2710/16034 , C12N2710/16734
摘要： The invention relates to veterinary medicine and the field of prevention, control, diagnosis or treatment of mastitis therein, and relates more specifically to bovine mastitis. The invention provides a viral agent causing mastitis and methods and means to treat, prevent, diagnose and control viral mastitis.
摘要翻译：本发明涉及兽医学及其预防，控制，诊断或治疗乳腺炎领域，更具体地涉及牛乳腺炎。本发明提供了引起乳腺炎的病毒剂以及治疗，预防，诊断和控制病毒性乳腺炎的方法和手段。

10. 发明申请

WO1998003659A1 AVIAN POLYNUCLEOTIDE VACCINE FORMULA 审中-公开
标题翻译： AVIAN POLYNUCLEOTIDE VACCINE公式
公开(公告)号：WO1998003659A1
公开(公告)日：1998-01-29
申请号：PCT/FR1997001326
申请日：1997-07-16
申请人： MERIAL , AUDONNET, Jean-Christophe , BOUCHARDON, Annabelle , RIVIERE, Michel
发明人： MERIAL
IPC分类号： C12N15/38
CPC分类号： C07K14/005 , A61K39/12 , A61K39/145 , A61K39/155 , A61K39/17 , A61K39/215 , A61K39/245 , A61K39/255 , A61K2039/51 , A61K2039/53 , A61K2039/552 , A61K2039/70 , C12N2710/16034 , C12N2710/16334 , C12N2720/10034 , C12N2750/10034 , C12N2760/16134 , C12N2760/18134 , C12N2760/18334 , C12N2770/20034 , C12N2770/22034 , C12N2770/32034 , C12N2770/32434
摘要： An avian vaccine formula including at least three polynucleotide vaccine valencies that each include a plasmid containing an avian pathogen valency gene capable of being expressed in vivo in host cells. Said valencies are selected from the group which consists of Marek's disease virus, Newcastle disease virus, infectious bursal disease virus, infectious bronchitis virus and infectious anaemia virus. The plasmids include one or more genes per valency, and said genes are selected from the group which consists of gB and gD for Marek's disease virus, HN and F for Newcastle disease virus, VP2 for infectious bursal disease virus, S, M and N for infectious bronchitis virus and C + NS1 for infectious anaemia virus.
摘要翻译：一种禽类疫苗配方，其包括至少三种多核苷酸疫苗价值，其各自包含含有能够在宿主细胞中体内表达的禽类病原体价态基因的质粒。所述价值选自马立克氏病病毒，新城疫病毒，传染性法氏囊病病毒，感染性支气管炎病毒和感染性贫血病毒组成的组。所述质粒包括每价的一种或多种基因，并且所述基因选自马立克氏病病毒的gB和gD，新城疫病毒的HN和F，感染性法氏囊病病毒的VP2，S，M和N的基因传染性支气管炎病毒和C + NS1感染性贫血病毒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式